Slim, Marleen A.
van Amstel, Rombout B. E.
Bos, Lieuwe D. J.
Cremer, Olaf L.
,
de Beer, Friso M.
Bos, Lieuwe D. J.
Glas, Gerie J.
Hoogendijk, Arie J.
van Hooijdonk, Roosmarijn T. M.
Horn, Janneke
Huson, Mischa A.
Schouten, Laura R. A.
Schultz, Marcus J.
Scicluna, Brendon P.
Straat, Marleen
van Vught, Lonneke A.
Wieske, Luuk
Wiewel, Maryse A.
Bonten, Esther Witteveen. Marc J. M.
Cremer, Olaf M.
Ong, David S. Y.
Frencken, Jos F.
Klouwenberg, Peter M. C. Klein
Koster‐Brouwer, Maria E.
van de Groep, Kirsten
Verboom, Diana M.
Wiersinga, W. Joost
van der Poll, Tom
van Vught, Lonneke A.
Funding for this research was provided by:
Horizon 2020 (847422)
Lung Foundation Netherlands
IMI COVID19 initiative
European Respiratory Society
Dutch lung foundation and Health Holland
Santhera
ZonMw (09150161910033)
Article History
Received: 12 December 2023
Accepted: 21 April 2024
First Online: 7 May 2024
Declarations
:
: This study was part of the Molecular Diagnosis and Risk Stratifcation of Sepsis (MARS) project (ClinicalTrials.gov identifer NCT0195033). The MARS project was a prospective observational study in two tertiary teaching hospitals in the Netherlands. Inclusion of patients was done using an opt-out method approved by the institutional review boards of both hospitals (IRB No. 10-056C).
: LDJB received consultancy fees from Scailyte, Santhera and Janssen en Janssen, and was on the advisory board of Sobi, Exvastat, Pfizer and Astra Zeneca, all paid to the institution. The other authors have no competing interests.